- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055452
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
April 21, 2024 updated by: China National Center for Cardiovascular Diseases
Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months.
The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function.
We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Hypertension is the leading risk factor of heart failure with preserved heart failure.
The overall control rate is about 16% in China.
Given the large amounts of hypertensive patients at pre-heart failure (stage B), it's critical to explore the effect of additional cardioprotective medication in addition to well-controlled blood pressure.
Sodium-glucose cotransporter-2 inhibitors (engagliflozin) have been shown to improve cardiac function or prognosis in patients with diabetes or heart failure.
However, whether it has a cardioprotective effect on hypertensive patients with pre-heart failure and without diabetes remains unknown.
We will conduct a multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes.
We will enroll 120 eligible patients randomized to receive a placebo or engagliflozin (10mg/d) for follow them for 6 months.
The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function.
The secondary endpoints include echocardiography or magnetic resonance imaging to measure structural and functional parameters, blood pressure, glucose, and blood biomarkers of inflammation and fibrosis.
We sought to comprehensively evaluate the effect of empagliflozin on the structure and function and explore the underlying mechanisms to provide insights and evidence for the prevention of heart failure in hypertensive patients.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xin Zheng, MD,PhD
- Phone Number: +86 13681077247
- Email: zhengxin@fuwai.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Recruiting
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Xin Zheng, MD,PhD
- Phone Number: +86 13681077247
- Email: zhengxin@fuwai.com
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518038
- Recruiting
- Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen
-
Contact:
- Wenyu Guo, MD,PhD
- Phone Number: 15813833652
- Email: 405514738@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
• Meeting all the following criteria:
- Aged 40 and above; less than 75 years.
- Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (<140/90 mmHg).
- The left atrial volume index measured by transthoracic echocardiography exceeds 34 mL/m², or the ratio of the average E/e' >9 and left atrial volume index >= 29 mL/m² measured by transthoracic echocardiography.
- Signing an informed consent form.
Exclusion Criteria:
• Exclusion criteria include any of the following conditions:
- History of diabetes.
- History of heart failure.
- History of coronary artery disease.
- Left ventricular systolic dysfunction, defined as LVEF < 50%.
- Systolic blood pressure < 100 mmHg.
- A history of arrhythmias such as atrial fibrillation, atrial flutter, frequent atrial premature contractions, and frequent ventricular premature contractions may impact the structural and functional aspects of the heart.
- Moderate and above valvular heart disease.
- Severe obstructive disease of the left ventricular outflow tract, including aortic valve stenosis.
- Visited within the past 1 month due to Genitourinary tract infection.
- Chronic kidney disease or estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73m².
- Alanine aminotransferase or aspartate aminotransferase levels > 3 times the upper limit of normal.
- Contraindications to taking SGLT2 inhibitors.
- Currently taking SGLT2 inhibitors, SGLT-1/2 inhibitors, or other antihyperglycemic medications (including metformin, glucagon-like peptide-1 receptor agonists, etc.).
- Pregnancy or planning pregnant, or currently breastfeeding.
- Malignant tumors or other severe illnesses with a life expectancy of less than 3 years.
- History of alcohol abuse or substance abuse within the past year.
- Mental disorders or communication barriers, cognitive impairments, or other severe illnesses that may affect participation in the study.
- Participation in or currently participating in other clinical trials within the last 3 months.
- Known poor compliance with study follow-up or study drug.
- Any condition or contraindication that makes a person intolerant to magnetic resonance imaging (MRI) or contraindicates MRI examination, such as the presence of implanted intracranial aneurysm clips, cardiac pacemakers or defibrillators, insulin pumps, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Each participant in the placebo group takes matching placebo.
|
Experimental: Empagliflozin
|
Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of left atrial volume index
Time Frame: 6 months
|
Changes in Left Atrial Volume Index (LAVI, mL/m2) as measured by MRI from baseline to 6 months.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated Glomerular Filtration Rate (eGFR)
Time Frame: 6 months
|
Change of eGFR
|
6 months
|
Change of cardiac structure and functional
Time Frame: 6 months
|
|
6 months
|
Biomarkers
Time Frame: 6 months
|
Biomarker concentrations were measured as follows:
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xin Zheng, MD,PhD, Chinese Academy of Medical Sciences, Fuwai Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2024
Primary Completion (Estimated)
October 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
September 14, 2023
First Submitted That Met QC Criteria
September 20, 2023
First Posted (Actual)
September 26, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 21, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-GSP-GG-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on Empagliflozin 10 MG
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
Damanhour UniversityRecruitingHeart Failure | Reduced Ejection Fraction Heart FailureEgypt
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland
-
Boehringer IngelheimCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedSubstance-Related Disorders | Depression | HIV InfectionsUnited States
-
The University of Hong KongResearch Grant CouncilRecruitingCirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 InhibitorsHong Kong